Detalles de la búsqueda
1.
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
N Engl J Med
; 390(17): 1560-1571, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587254
2.
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Curr Atheroscler Rep
; 24(7): 585-597, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35524914
3.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30403574
4.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Am Heart J
; 231: 121-127, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33065120
5.
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.
Br J Clin Pharmacol
; 87(6): 2558-2571, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217027
6.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Circulation
; 140(2): 103-112, 2019 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31117810
7.
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.
Circulation
; 139(7): 863-873, 2019 02 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586739
8.
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).
Eur Heart J
; 40(25): 2070-2085, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29992264
9.
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Eur Heart J
; 40(33): 2801-2809, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31121022
10.
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Am Heart J
; 208: 81-90, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30580130
11.
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
Am Heart J
; 201: 25-32, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29910052
12.
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Am Heart J
; 196: 28-35, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29421012
13.
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
Blood Cells Mol Dis
; 72: 37-43, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30055940
14.
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.
J Thromb Thrombolysis
; 45(4): 469-476, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29582212
15.
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Eur Heart J
; 38(11): 804-810, 2017 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28363222
16.
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Circulation
; 134(24): 1918-1930, 2016 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27881559
17.
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials.
Circulation
; 133(16): 1560-73, 2016 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26957532
18.
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
Am Heart J
; 187: 53-61, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28454808
19.
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
Am Heart J
; 187: 194-203, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28454804
20.
Consensus or Controversy?: Evolution of Criteria for Myocardial Infarction After Percutaneous Coronary Intervention.
Clin Chem
; 63(1): 82-90, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28062613